The U.S. Food and Drug Administration (FDA) advised IQ Formulations that an analysis of a sample from Hydravax Lot #2458 (Exp # 07/16) revealed the presence of an undeclared ingredient, identified as a diuretic. Diuretics are prescription drugs. The product is sold nationwide in stores and by mail order in 45-capsule bottles, to aid in weight loss by eliminating water weight.
The company’s press release—posted on the FDA website—lists a number of possible effects of using a diuretic, including an electrolyte imbalance due to water loss. Other symptoms include: polyuria (excessive urination), nausea, vomiting, weakness, lassitude, fever, flushed face, and hyperactive deep tendon reflexes. According to IQ Formulations, fluid and electrolyte imbalances are the most serious concern. Overdosing with a diuretic has been associated with hypokalemia, hypochloremia, hyponatremia, dehydration, lethargy and gastrointestinal irritation. People experiencing these problems should seek immediate medical attention.
To date, no illnesses or consumer complaints have been reported. Consumers should contact a physician or healthcare provider if they experience any problems that could be related to the taking or using of the product.
IQ Formulations has suspended production of Hydravax while investigating the source of the potential unlisted ingredient.
The company recommends that consumers return Hydravax to the place of purchase for a full refund. Consumers and distributors can contact the company for information about the recall at Recall@iqformulations.com or by phone at 800.626.1022, Monday through Friday, 9 a.m. to 5 p.m. EST.